Flavoured nicotine powder inhaler
US-2017035108-A1 · Feb 9, 2017 · US
US9896429B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9896429-B2 |
| Application number | US-201514951939-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 25, 2015 |
| Priority date | May 27, 2014 |
| Publication date | Feb 20, 2018 |
| Grant date | Feb 20, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The invention provides certain nicotine salts, co-crystals, and salt co-crystals and provides novel polymorphic forms of certain nicotine salts. In particular, nicotine salts with orotic acid are described. The invention further provides methods of preparation and characterization of such nicotine salts. In addition, tobacco products, including smoking articles, smokeless tobacco products, and electronic smoking articles comprising nicotine salts, co-crystals, and/or salt co-crystals are also provided.
Opening claim text (preview).
What is claimed: 1. A bis-orotic acid salt-co-crystal of nicotine and orotic acid, characterized by an X-ray powder diffraction pattern having peaks at one or more of the following 2-theta diffraction angles: 8.8, 13.4, 17.7, 26.5, and 29.3. 2. The salt-co-crystal of claim 1 , wherein at least about 50% of the salt-co-crystal is in crystalline form. 3. A pharmaceutical product comprising the salt-co-crystal of nicotine and orotic acid of claim 1 and one or more pharmaceutically acceptable excipients. 4. The pharmaceutical product of claim 3 , in a form selected from the group consisting of a pill, tablet, lozenge, capsule, caplet, pouch, gum, inhaler, solution, and cream. 5. A method of preparing the salt-co-crystal of claim 1 , comprising combining nicotine and orotic acid to form a solid and isolating the solid. 6. The method of claim 5 , wherein the combining comprises mixing the nicotine and orotic acid in THF, ethanol, or a mixture thereof. 7. The pharmaceutical product of claim 3 , wherein the one or more pharmaceutically acceptable excipients comprise isomalt.
Two oxygen atoms · CPC title
directly linked by a ring-member-to-ring-member bond · CPC title
Tobacco for pipes, for cigars, e.g. cigar inserts, or for cigarettes; Chewing tobacco; Snuff (reconstituted tobacco products A24B3/14) · CPC title
Fumaric acid · CPC title
electrical · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.